Anika Therapeutics (NASDAQ: ANIK) reported Q1 EPS of ($0.06), $0.02 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $26.17 million versus the consensus estimate of $28.13 million.

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.